BP 294

Drug Profile

BP 294

Alternative Names: FUB 94

Latest Information Update: 28 Nov 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bioprojet
  • Developer Bioprojet; INSERM
  • Class Analgesics; Anti-inflammatories; Antiasthmatics; Antiulcers; Imidazoles
  • Mechanism of Action Histamine H3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Inflammation; Pain; Peptic ulcer

Most Recent Events

  • 15 May 2001 A study has been added to the Pain pharmacodynamics section
  • 08 Feb 2000 A study has been added to the Peptic Ulcer disease pharmacodynamics section
  • 22 Jul 1997 Preclinical development for Inflammation in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top